Prokidney Corp. (NASDAQ:PROK)
| Market Cap | 527.92M-51.8% |
| Revenue (ttm) | 818.00K+55.2% |
| Net Income | -86.71M-19.6% |
| EPS | -0.57+0.0% |
| Shares Out | 148.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 831,085 |
| Open | 1.56 |
| Previous Close | 1.60 |
| Day's Range | 1.55 - 1.59 |
| 52-Week Range | 1.30 - 3.48 |
| Beta | 1.80 |
| Analysts | Buy |
| Price Target | 4.67(+197.45%) |
| Earnings Date | Nov 9, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About PROK
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PROK stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PROK holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PROK's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PROK Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PROK Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Equity-based compensation | $10.54M | 98.60% |
| Rental income | $150.00K | 1.40% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New PROK patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PROK from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PROK
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $4.30M |
| VXFVanguard Extended Market ETF | $2.41M |
| SCHASchwab U.S. Small-Cap ETF | $1.32M |
| IWOiShares Russell 2000 Growth ETF | $1.10M |
| VTWOVanguard Russell 2000 ETF | $817.69K |
| SURISimplify Propel Opportunities ETF | $759.47K |
Estimated from each fund’s disclosed top holdings × AUM
PROK Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PROK’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score